<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="1" offset="0" totalResults="1"><SearchResults><Trial Id="305974"><Indications><Indication>Abdominal aortic aneurysm</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Iron metabolism modulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>University of Edinburgh</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2017-08-02T00:00:00Z</DateChangeLast><DateEnd>2016-09-07T00:00:00Z</DateEnd><DateStart>2012-09-07T00:00:00Z</DateStart><Identifiers><Identifier>11/20/03</Identifier><Identifier>2012-002488-25</Identifier><Identifier>ISRCTN76413758</Identifier><Identifier>MA3RS</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ferumoxytol alone</Intervention><Intervention>magnetic resonance imaging alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>350</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study proposed to assess this novel approach to identify aneurysms that were likely to expand more rapidly and potentially rupture. This technique would provide potentially important additional information to the current simplistic gold-standard of ultrasound measurement of aneurysm diameter. The primary objective of the study was to determine whether normal uptake of ultra small supermagnetic particles of iron oxide (USPIO) provides incremental risk prediction in addition to standard risk markers</Teaser><TrialCategories><Category>Diagnostic</Category><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other cardiovascular disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MA3RS: Magnetic resonance imaging (MRI) for abdominal aortic aneurysms to predict rupture or surgery</TitleDisplay><PatientSegmentTerms><PatientSegment>Other cardiovascular disease - Subjects with specific disease - Subjects with abdominal aortic aneurysm</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood flow </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Matrix Metalloproteinases </BiomarkerName><BiomarkerName> Pulse Wave Transit Time</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Prof Newby</Name></ContactNames></Trial></SearchResults></trialResultsOutput>